Full Breakdown
Shingrix Vaccination Associated with a Modest Reduction in Cardiovascular Events
8/26/2026, 7:52:37 PM
Core Findings
A recent observational analysis of U.S. health records found that adults aged 60 and older who received the recombinant shingles vaccine Shingrix experienced about a 12 % lower risk of cardiovascular diagnoses—including heart attack, heart failure and stroke—during the first three and a half years after vaccination. By the end of follow-up, the overall risk was 4 % lower compared with those who had received the earlier live-virus vaccine Zostavax. The researchers liken the effect to that of a daily antihypertensive medication if confirmed in clinical trials.
Background & Context
Shingles results from reactivation of the varicella-zoster virus. Zostavax, introduced in 2006, uses a weakened live virus; in 2017 the United States shifted its recommendation to Shingrix, a protein-subunit vaccine with the AS01 adjuvant. Shingrix is also offered in the United Kingdom to anyone turning 65 on or after September 1 2023. Prior observational work suggested a link between shingles vaccination and reduced cardiovascular risk, but those studies compared vaccinated with never-vaccinated people, leaving results vulnerable to lifestyle confounding.
Data & Statistics
- Cohort size: ? 70,000 adults >= 60 years, tracked for up to seven years.
- Relative risk reduction: 12 % lower cardiovascular events in the first 3.5 years; 4 % lower by the end of follow-up.
- Vaccine uptake: About one-third of eligible U.S. adults receive Shingrix.
Official Statements & Responses
Researchers note the benefit may stem from reduced inflammation after preventing shingles or broader immune modulation by AS01. John Tregoning of Imperial College London said the vaccine’s primary purpose is shingles prevention, but added that potential added protection against heart disease makes it “worthwhile” for older adults. Betty Raman, Oxford, highlighted laboratory data suggesting AS01 reprograms monocytes to produce fewer inflammatory cytokines implicated in arterial plaque formation.
Conflicting Reports & Gaps
- Relative vs. absolute risk: The 12 % figure is relative; the absolute difference in event rates is modest.
- Causality: Observational designs cannot fully eliminate differences between vaccine groups (e.g., health-seeking behavior).
- Mechanism: It remains uncertain whether the benefit arises from preventing shingles-related inflammation or from broader immune effects of AS01.
Verbatim Quotes
- “If confirmed in clinical trials, vaccinating older adults against shingles could prevent hundreds of thousands of coronary heart diseases, strokes and cases of heart failure worldwide, making it one of the most impactful interventions we could offer to protect both the brain and the heart in later life. The effect might be enormous.” — Brown University, assistant professor
- “If confirmed in a [randomised controlled trial], the effect of Shingrix would be equivalent to antihypertensives,” — Max Taquet, University of Oxford
- “A randomised trial would be the best way to confidently answer whether recombinant vaccines do provide the benefits seen here versus live vaccines, but until such a trial is done this study provides some of the best-quality observational evidence supporting an effect of recombinant v live vaccines for cardiovascular outcomes.” — Brown University, assistant professor
What’s Next
A large randomized trial in Denmark is enrolling more than 160,000 adults >= 65 years to receive either Shingrix or no shingles vaccine, with primary results anticipated by 2027. Additional trials aim to clarify the causal relationship between Shingrix and cardiovascular outcomes and to assess any neuroprotective effects.
